Role of omalizumab and steroids in Churg-Strauss syndrome.

摘要

Rotavirus is the most common cause of acute gastroenteritis in young children worldwide, and accounts for more than 2.5 million deaths annually.1 Two live oral vaccines for rotavirus are currently licensed: RotaTeq (CSL Limited, Parkville, Victoria, Australia), a pentavalent bovine-human reassortant vaccine, and Rotarix (GlaxoSmithKline [GSK] Australia Pty Ltd, Boronia, Victoria, Australia), a human monovalent vaccine. Both vaccines became available on the Australian National Immunization Program in July 2007 with RotaTeq given on the National Immunization Program schedule at 2,4, and 6 months of age. Live vaccines such as measles mumps rubella (MMR) are generally contraindicated in immunosuppressed populations because of potential morbidity and mortality.2 This has not been applied to rotavirus vaccines, in which risk of vaccine-associated disease is felt to be less than the risk from being exposed to natural infection.2 Current guidelines support the administration of rotavirus vaccine to children infected with HIV, the largest immunosuppressed population studied to date.3 The side effect profile is likely to involve gastrointestinal symptoms (vomiting and diarrhea).